Company Spotlight: Amadix

Amadix is focused on developing innovative technologies for cancer diagnosis. Can you share more about your current solutions and how they are improving patient survival rates?

Amadix is a leading molecular diagnostics company specializing in liquid biopsy technologies, powered by its AI platform, that integrates molecular biomarkers, imaging, and clinical data to train predictive models for early cancer detection. Its mission is to extend lives through disruptive technologies that enable tumor detection years before symptoms appear.

There is a critical need to improve early detection of colorectal cancer (CRC) as over 60% of cases are diagnosed late, leading to more complex treatment, higher costs, and a five-year survival rate below 14%, compared to over 90% when detected early.

PreveCol solution is a blood-based test designed for average-risk individuals aged 45 to 85, offering a more patient-friendly option for early CRC detection and was granted FDA Breakthrough Device Designation due to its high accuracy to detect precancerous lesions, when we can prevent CRC from developing.

Amadix is also advancing its pipeline of non-invasive cancer diagnostics, including two blood tests for risk assessment of lung and pancreatic cancer in patients with prior inconclusive tests, to detect the cancer earlier, when it is most curable.

What are the biggest challenges in diagnosing cancer early, and how is Amadix addressing these challenges through your innovations?

The main challenge in early detection is to create screening techniques and programs that are widely accepted by the population. Many of the most common techniques currently in use, such as stool tests or invasive tests, have low adherence, mainly because they are uncomfortable to perform or highly invasive. Additionally, non-invasive CRC screening alternatives lack accuracy to detect cancer early, when it is most curable.

At Amadix, we develop blood-based testshaving higher adherence among the screening population that is used to undergo routine lab work. Our CRC screening test was recently granted Breakthrough Device Designation by the FDA due to its highest accuracy to detect precancerous lesions that may potentially prevent the cancer from developing.

Amadix’s work has the potential to transform cancer care. How do you see your technologies fitting into the broader healthcare ecosystem, and what partnerships or collaborations are key to achieving your goals?

The technology we use at Amadix is precision medicine, which is the future of healthcare. To continue its development and realize its full potential, it requires key partnerships and alliances.

We are currently in the process of internationalizing our PreveCol product, and in order to reach other markets, it is essential to reach agreements with partners responsible for introducing new solutions in the laboratories and commercial partners that reach our target prescriber (such as GIs and GPs in the case of PreveCol), who are involved in CRC screening programs in order to create awareness of new and improved screening methods. Additionally, we will need KOLs that support the inclusion of our tests in major guidelines, reimbursement via public health and main private payors, to facilitate access to individuals.

PreveCol, as an accurate blood test, is well positioned to not only increase adherence in CRC screening programs, but also reduce expensive cancer treatment costs for the healthcare system, with its capacity to detect cancer earlier.

What role does investment play in advancing cancer diagnostics, and what would you like the life sciences investment community to understand about the potential of Amadix’s work?

In this sector, many years of research are required before products can be launched on the market, so it is essential to attract the attention of large investors to finance the R&D&I necessary to develop our products. Without the confidence of investors, it would have been impossible for us to bring PreveCol to market.

PreveCol TAM (total addressable market) just in the US is estimated to be almost $20B, with 117M individuals eligible for CRC screening and a huge opportunity as 40% have never been screened before.

We also have two products under development (DiagnoLung and PancreaDix) that target critical unmet needs, assessing the risk of lung and pancreatic cancer in individuals with inconclusive prior tests. And most importantly, the AI platform that has supported the development of these tests will enable us to scale and grow our pipeline to continue solving unmet needs in the diagnostic space focused on early cancer detection.

Looking ahead, what excites you most about the future of cancer diagnostics and the role Amadix will play in shaping that future? What opportunities do you see for innovation and growth in the industry

I believe that in a few years, early cancer detection and screening programs will be much simpler and more accessible to the vast majority of the population. This will enable us to avoid reaching advanced stages of cancer in many cases. And thus, be able to treat the disease and even be able to prevent it by detecting its precancerous stages.

As I said in one of the previous questions, we are developing the medicine of the future. That is why I believe that, if we continue to invest in research, the potential for growth and innovation in the industry is immense. It is still a dream, but techniques such as those we already use for cancer detection, thanks to AI, could in the future be applied to the detection or diagnosis of other diseases, while also making them more accessible for the healthcare ecosystem.

The science sector, and especially entrepreneurship, is in many cases male dominated. What do you think can be done to promote female entrepreneurship?

In my opinion education is the fundamental pillar on which society must rely to promote female entrepreneurship. It is common for toys given to girls to stimulate curiosity and mathematical thinking less than those given to boys. That is why it is very important to change the models we give girls from an early age, something we are already doing and can certainly improve on.

Another barrier that women encounter is balancing work and family life. In many cases, this is a real limitation that we must address as a society, implementing measures in both research centres and companies to help balance family and work as much as possible. We need more women making decisions in positions of responsibility.

Find out more at: www.amadix.com